Results 181 to 190 of about 83,002 (289)

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers

open access: yesMovement Disorders, EarlyView.
Abstract Background GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease.
Julian Agin‐Liebes   +7 more
wiley   +1 more source

Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Parkinson's disease is mainly characterized by dopaminergic neurodegeneration in the substantia nigra pars compacta (SNc) and α‐synuclein accumulation. The locus coeruleus (LC) is also affected in Parkinson's disease and linked to some nonmotor symptoms, but the extent and timing of its degeneration remain unclear.
Megan Carrillo   +6 more
wiley   +1 more source

Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao   +8 more
wiley   +1 more source

α-synuclein positivity is associated with decline in brain microstructure in the Alzheimer's disease spectrum. [PDF]

open access: yesAlzheimers Res Ther
Mak E   +13 more
europepmc   +1 more source

Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Acute ischemic stroke (AIS) in those with Parkinson's disease (PD) is a growing healthcare burden but mortality studies are significantly lacking. Objective To map short‐ and long‐term survival, stratified by relevant comorbidities and stroke characteristics.
Lee E. Neilson   +3 more
wiley   +1 more source

Correction: α-Synuclein modulates tau spreading in mouse brains. [PDF]

open access: yesJ Exp Med
Bassil F   +10 more
europepmc   +1 more source

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T SNCA mutation usually leads to a severe form of PD.
Nikolaos Papagiannakis   +213 more
wiley   +1 more source

When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions

open access: yesMovement Disorders, EarlyView.
Abstract Although Parkinson's disease (PD) is classically defined by its motor features, non‐motor symptoms exert a substantial and often under‐recognized influence on disease trajectory. Among these, weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood.
Ellie D. Gabriel   +6 more
wiley   +1 more source

Elevation of Stearoyl‐Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum

open access: yesMovement Disorders, EarlyView.
Abstract Background Emerging evidence indicates that dysregulation of monounsaturated fatty acids (MUFAs), synthesized by the enzyme stearoyl‐coenzyme A desaturase (SCD), impacts on α‐synuclein pathology in the Parkinson's disease (PD) brain. Objective The objective of this study was to analyze SCD and MUFA‐enriched lipids in the periphery of patients ...
Finula I. Isik   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy